Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III long-term extension study of S-877503 (guanfacine) in adults with ADHD
jRCT2080223177Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Shionogi & Co., Ltd. Primary endpoint: Long-term safety of S-877503 (guanfacine). Started Apr 2016; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2080223177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223177.